461 related articles for article (PubMed ID: 23852808)
1. Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition.
Roepman P; Schlicker A; Tabernero J; Majewski I; Tian S; Moreno V; Snel MH; Chresta CM; Rosenberg R; Nitsche U; Macarulla T; Capella G; Salazar R; Orphanides G; Wessels LF; Bernards R; Simon IM
Int J Cancer; 2014 Feb; 134(3):552-62. PubMed ID: 23852808
[TBL] [Abstract][Full Text] [Related]
2. The Impact of Mismatch Repair Status in Colorectal Cancer on the Decision to Treat With Adjuvant Chemotherapy: An Australian Population-Based Multicenter Study.
He EY; Hawkins NJ; Mak G; Roncolato F; Goldstein D; Liauw W; Clingan P; Chin M; Ward RL
Oncologist; 2016 May; 21(5):618-25. PubMed ID: 27009937
[TBL] [Abstract][Full Text] [Related]
3. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer.
Jover R; Zapater P; Castells A; Llor X; Andreu M; Cubiella J; Piñol V; Xicola RM; Bujanda L; Reñé JM; Clofent J; Bessa X; Morillas JD; Nicolás-Pérez D; Payá A; Alenda C;
Gut; 2006 Jun; 55(6):848-55. PubMed ID: 16299036
[TBL] [Abstract][Full Text] [Related]
4. Role of Deficient Mismatch Repair in the Personalized Management of Colorectal Cancer.
Zhang CM; Lv JF; Gong L; Yu LY; Chen XP; Zhou HH; Fan L
Int J Environ Res Public Health; 2016 Sep; 13(9):. PubMed ID: 27618077
[TBL] [Abstract][Full Text] [Related]
5. [Molecular biology in clinical cancer research: the example of digestive cancers].
Lièvre A; Laurent-Puig P
Rev Epidemiol Sante Publique; 2005 Jun; 53(3):267-82. PubMed ID: 16227914
[TBL] [Abstract][Full Text] [Related]
6. An immune, stroma, and epithelial-mesenchymal transition-related signature for predicting recurrence and chemotherapy benefit in stage II-III colorectal cancer.
Cai D; Wang W; Zhong ME; Fan D; Liu X; Li CH; Huang ZP; Zhu Q; Lv MY; Hu C; Duan X; Wu XJ; Gao F
Cancer Med; 2023 Apr; 12(7):8924-8936. PubMed ID: 36629124
[TBL] [Abstract][Full Text] [Related]
7. The evolution of our molecular understanding of colorectal cancer: what we are doing now, what the future holds, and how tumor profiling is just the beginning.
Dienstmann R; Salazar R; Tabernero J
Am Soc Clin Oncol Educ Book; 2014; ():91-9. PubMed ID: 24857065
[TBL] [Abstract][Full Text] [Related]
8. [DNA mismatch repair and BRAF status in colorectal cancer: Interest for the therapeutic management?].
Cohen R; Cervera P; Svrcek M; Dumont C; Garcia ML; Chibaudel B; de Gramont A; Pocard M; Duval A; Fléjou JF; André T
Bull Cancer; 2015 Jun; 102(6 Suppl 1):S72-81. PubMed ID: 26118880
[TBL] [Abstract][Full Text] [Related]
9. Pathological complete response with anti-PD-1 therapy in a patient with microsatellite instable high, BRAF mutant metastatic colon cancer: a case report and review of literature.
Sehdev A; Cramer HM; Ibrahim AA; Younger AE; O'Neil BH
Discov Med; 2016 May; 21(117):341-7. PubMed ID: 27355330
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological predictors of benefit from adjuvant chemotherapy for stage C colorectal cancer: Microsatellite unstable cases benefit.
Thomas ML; Hewett PJ; Ruszkiewicz AR; Moore JW
Asia Pac J Clin Oncol; 2015 Dec; 11(4):343-51. PubMed ID: 26471980
[TBL] [Abstract][Full Text] [Related]
11. Mismatch repair deficient colorectal cancer in the era of personalized treatment.
Hewish M; Lord CJ; Martin SA; Cunningham D; Ashworth A
Nat Rev Clin Oncol; 2010 Apr; 7(4):197-208. PubMed ID: 20177404
[TBL] [Abstract][Full Text] [Related]
12. Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy.
Murcia O; Juárez M; Rodríguez-Soler M; Hernández-Illán E; Giner-Calabuig M; Alustiza M; Egoavil C; Castillejo A; Alenda C; Barberá V; Mangas-Sanjuan C; Yuste A; Bujanda L; Clofent J; Andreu M; Castells A; Llor X; Zapater P; Jover R
PLoS One; 2018; 13(9):e0203051. PubMed ID: 30188916
[TBL] [Abstract][Full Text] [Related]
13. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.
Ribic CM; Sargent DJ; Moore MJ; Thibodeau SN; French AJ; Goldberg RM; Hamilton SR; Laurent-Puig P; Gryfe R; Shepherd LE; Tu D; Redston M; Gallinger S
N Engl J Med; 2003 Jul; 349(3):247-57. PubMed ID: 12867608
[TBL] [Abstract][Full Text] [Related]
14. Topoisomerase-1 and -2A gene copy numbers are elevated in mismatch repair-proficient colorectal cancers.
Sønderstrup IM; Nygård SB; Poulsen TS; Linnemann D; Stenvang J; Nielsen HJ; Bartek J; Brünner N; Nørgaard P; Riis L
Mol Oncol; 2015 Jun; 9(6):1207-17. PubMed ID: 25777966
[TBL] [Abstract][Full Text] [Related]
15. Molecular subtypes in early colorectal cancer associated with clinical features and patient prognosis.
Gil-Raga M; Jantus-Lewintre E; Gallach S; Giner-Bosch V; Frangi-Caregnato A; Safont-Aguilera MJ; Garde-Noguera J; Zorraquino-Pina E; García-Martínez M; Camps-Herrero C
Clin Transl Oncol; 2018 Nov; 20(11):1422-1429. PubMed ID: 29802524
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy of MMR-deficient colorectal cancer.
Devaud N; Gallinger S
Fam Cancer; 2013 Jun; 12(2):301-6. PubMed ID: 23539382
[TBL] [Abstract][Full Text] [Related]
17. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Le DT; Uram JN; Wang H; Bartlett BR; Kemberling H; Eyring AD; Skora AD; Luber BS; Azad NS; Laheru D; Biedrzycki B; Donehower RC; Zaheer A; Fisher GA; Crocenzi TS; Lee JJ; Duffy SM; Goldberg RM; de la Chapelle A; Koshiji M; Bhaijee F; Huebner T; Hruban RH; Wood LD; Cuka N; Pardoll DM; Papadopoulos N; Kinzler KW; Zhou S; Cornish TC; Taube JM; Anders RA; Eshleman JR; Vogelstein B; Diaz LA
N Engl J Med; 2015 Jun; 372(26):2509-20. PubMed ID: 26028255
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review.
Biller LH; Schrag D
JAMA; 2021 Feb; 325(7):669-685. PubMed ID: 33591350
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological features of mismatch repair protein expression patterns in colorectal cancer.
Lee CT; Chow NH; Chen YL; Ho CL; Yeh YM; Lin SC; Lin PC; Lin BW; Chu CA; Tsai HW; Lee JC
Pathol Res Pract; 2021 Jan; 217():153288. PubMed ID: 33276219
[TBL] [Abstract][Full Text] [Related]
20. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy.
Hemminki A; Mecklin JP; Järvinen H; Aaltonen LA; Joensuu H
Gastroenterology; 2000 Oct; 119(4):921-8. PubMed ID: 11040179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]